Temporary Inhibition of Moloney-murine Sarcoma Virus (M-MSV) Induced-tumours by Adoptive Transfer of Ricin-treated T-lymphocytes

Overview

Journal Br J Cancer

Specialty Oncology

Date 1987 Apr 1

PMID 2437947

Citations 5

Authors

V Cerundolo

P Zanovello

D McIntosh

R Fabbris

A J Davies

D Collavo

Affiliations

Soon will be listed here.

Abstract

The potential use of tumour-specific T-lymphocytes loaded with ricin in cell targeting experiments was investigated. Moloney-murine sarcoma virus (M-MSV)-specific T-lymphocytes, obtained in mass mixed leucocyte-tumour cell culture (MLTC) and a M-MSV-specific cytotoxic T-lymphocyte (CTL) clone, were incubated with 125I-labelled ricin in order to evaluate toxin uptake and release. The internalized ricin (4.5 X 10(-17) mol and 6.5 X 10(-17) mol per 10(2) MLTC and CTL clone cells, respectively) was released rapidly during the first 30 min following treatment, and at a constant but slower rate over the next few hours. The cytotoxic activity of ricin-treated cells evaluated against antigen-related target cells, in a short term incubation 51Cr release assay, was unaffected during the first 30 min after treatment but decreased with time over the next few hours. However, the growth of antigen related as well as of unrelated tumour cells was strongly inhibited by the addition of ricin-treated cells to the culture system, thus indicating that released ricin is toxic for untreated target cells. The in vivo localization pattern of ricin-treated radiolabelled MLTC cells was found to be comparable with that of untreated cells 1 h after i.v. injection into syngeneic sublethally irradiated mice. After 6 h, however, more radiolabel was recovered from the liver of mice receiving ricin-treated MLTC cells. Ricin-treated M-MSV-specific T-lymphocytes were injected i.v. into tumour bearing sublethally irradiated mice. A temporary tumour growth inhibition (up to 6 days) was achieved following transfer of low doses of ricin-treated MLTC or CTL clone cells (1 X 10(6) and 0.5 X 10(6), respectively). In contrast, in M-MSV injected control mice, receiving only free toxin (from 5 to 20 ng) or untreated tumour-specific effector cell tumours grew progressively. The therapeutic effect was apparently specific since the injection of ricin-treated alloreactive T-lymphocytes did not influence tumour growth. These results suggest that M-MSV-specific T-lymphocytes loaded with ricin can deliver toxin to the target tumour mass and have a transient therapeutic effect.

Citing Articles

Adoptive Transfer of Photosensitizer-Loaded Cytotoxic T Cells for Combinational Photodynamic Therapy and Cancer Immuno-Therapy.

Blaudszun A, Kim W, Um W, Yoon H, Shim M, Kim K Pharmaceutics. 2023; 15(4).

PMID: 37111779 PMC: 10143374. DOI: 10.3390/pharmaceutics15041295.

Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases.

Quintieri L, Rosato A, Amboldi N, Vizler C, Ballinari D, Zanovello P Br J Cancer. 1999; 79(7-8):1067-73.

PMID: 10098738 PMC: 2362260. DOI: 10.1038/sj.bjc.6690171.

Interaction of lymphokine-activated killer cells with susceptible targets does not induce second messenger generation and cytolytic granule exocytosis.

Zanovello P, Rosato A, Bronte V, Cerundolo V, Treves S, Di Virgilio F J Exp Med. 1989; 170(3):665-77.

PMID: 2769181 PMC: 2189428. DOI: 10.1084/jem.170.3.665.

Lymphocyte targeted ricin as a potential therapy for lymphoid malignancy. I. Targeting efficiency.

Ramsden C, Drayson M, Bell E Br J Cancer. 1991; 63(5):699-704.

PMID: 2039695 PMC: 1972389. DOI: 10.1038/bjc.1991.158.

Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases.

Zanovello P, Rosato A, Bronte V, Mandruzzato S, Cerundolo V, Collavo D Cancer Immunol Immunother. 1992; 35(1):27-32.

PMID: 1611620 PMC: 11038254. DOI: 10.1007/BF01741051.

References

Lin J, Tserng K, Chen C, Lin L, TUNG T . Abrin and ricin: new anti-tumour substances. Nature. 1970; 227(5255):292-3. DOI: 10.1038/227292a0. View

Cerottini J, BRUNNER K . Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv Immunol. 1974; 18:67-132. DOI: 10.1016/s0065-2776(08)60308-9. View

Henney C . On the mechanism of T-cell mediated cytolysis. Transplant Rev. 1973; 17(0):37-70. DOI: 10.1111/j.1600-065x.1973.tb00123.x. View

Martz E . Early steps in specific tumor cell lysis by sensitized mouse T lymphocytes. I. Resolution and characterization. J Immunol. 1975; 115(1):261-7. View

Fodstad O, Olsnes S, Pihl A . Toxicity, distribution and elimination of the cancerostatic lectins abrin and ricin after parenteral injection into mice. Br J Cancer. 1976; 34(4):418-25. PMC: 2025264. DOI: 10.1038/bjc.1976.187. View

Fodstad O, Olsnes S, Pihl A . Inhibitory effect of abrin and ricin on the growth of transplantable murine tumors and of abrin on human cancers in nude mice. Cancer Res. 1977; 37(12):4559-67. View

Sandvig K, Olsnes S, Pihl A . Binding, uptake and degradation of the toxic proteins abrin and ricin by toxin-resistant cell variants. Eur J Biochem. 1978; 82(1):13-23. DOI: 10.1111/j.1432-1033.1978.tb11992.x. View

Collavo D, Parenti A, Biasi G, Chieco-Bianchi L, Colombatti A . Secondary in vitro generation of cytolytic T-lymphocytes (CTL's) in the murine sarcoma virus system. Virus-specific CTL induction across the H-2 barrier. J Natl Cancer Inst. 1978; 61(3):885-90. View

Fodstad O, Pihl A . Effect of ricin and abrin on survival of L1210 leukemic mice and on leukemic and normal bone-marrow cells. Int J Cancer. 1978; 22(5):558-63. DOI: 10.1002/ijc.2910220509. View

10.

Sandvig K, Olsnes S . Effect of temperature on the uptake, excretion and degradation of abrin and ricin by HeLa cells. Exp Cell Res. 1979; 121(1):15-25. DOI: 10.1016/0014-4827(79)90439-7. View

11.

Collavo D, Zanovello P, LEUCHARS E, Davies A, Chieco-Bianchi L, Biasi G . Moloney murine sarcoma virus oncogenesis in T-lymphocyte-deprived mice: biologic and immunologic studies. J Natl Cancer Inst. 1980; 64(1):97-104. View

12.

Eiklid K, Olsnes S, Pihl A . Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res. 1980; 126(2):321-6. DOI: 10.1016/0014-4827(80)90270-0. View

13.

Dailey M, Fathman C, Butcher E, Pillemer E, Weissman I . Abnormal migration of T lymphocyte clones. J Immunol. 1982; 128(5):2134-6. View

14.

Carroll A, Palladino M, Oettgen H, de Sousa M . In vivo localization of cloned IL-2-dependent T cells. Cell Immunol. 1983; 76(1):69-80. DOI: 10.1016/0008-8749(83)90349-0. View

15.

McIntosh D, EDWARDS D, Davies A . Transfer of ricin toxicity by spleen cells. Toxicon. 1984; 22(2):293-9. DOI: 10.1016/0041-0101(84)90029-1. View

16.

Engers H, Lahaye T, SORENSON G, Glasebrook A, Horvath C, BRUNNER K . Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones. J Immunol. 1984; 133(3):1664-70. View

17.

De Jong W, van de Plas M, Steerenberg P, Kruizinga W, Ruitenberg E . Selective localization of tumor-immune spleen cells at the tumor challenge site after adoptive transfer of line 10 tumor immunity in strain 2 guinea pigs. J Immunol. 1985; 134(3):2032-40. View

18.

Sparshott S, Forrester J, McIntosh D, Wood C, Davies A, Ford W . The carriage and delivery of substances to lymphatic tissues by recirculating lymphocytes. I. The concentration of ricin in lymphocyte traffic areas. Immunology. 1985; 54(4):731-43. PMC: 1453558. View